Rachelle Doody (Switzerland)
F. Hoffman LaRoche
PD Neuroscience
Rachelle Doody MD, PhD is Vice President, Global Head of Neurodegeneration and the Alzheimer's Disease and Neurodegeneration Franchise Head in Product Development, Neuroscience at F. Hoffman LaRoche and Genentech. She oversees late stage drug development for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other neurodegenerative disorders. Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she had founded and directed the Alzheimer’s Disease and Memory Disorders Center and is now Distinguished Professor Emeritus. She has served on the steering committees for the Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI), the executive committee for the Alzheimer’s Therapeutic Research Institute (ATRI), and is currently Chair of the US Alzheimer’s Association Research Roundtable. She has contributed to efforts to globalize the diagnosis and treatment of AD and has published over 200 original research articles. In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. Dr. Doody has received Distinguished Alumni Award from Rice University in 2009, Distinguished Faculty Award from Baylor College of Medicine in 2011, and a Lifetime Achievement Award from the Clinical Trials in Alzheimer’s Disease Society in 2018.

Presenter of 1 Presentation

 Conference Calendar

PRE-RECORDED: TACKLING NEURODEGENERATIVE DISEASES: USING SYNERGIES ACROSS DISEASE AREAS TO SPEED DRUG DEVELOPMENT FOR PATIENTS

Session Name
1520 - AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 4 (ID 73)
Session Type
SYMPOSIUM
Date
Sat, 19.03.2022
Session Time
09:10 AM - 11:10 AM
Room
ONSITE: 112
Lecture Time
09:40 AM - 09:55 AM
Presenter

Abstract

Abstract Body

Objective: Neurodegenerative diseases share certain features: they are often characterized by accumulation of abnormal, toxic proteins; they have long prodromal periods; their clinical onset is often enabled and/or accelerated by aging. On the other hand, they differ in many important ways, including inheritance patterns; clinical symptoms --reflecting selective vulnerability of cell types and/or networks; and the time course by which they impair the nervous system. This discussion reviews how the evolution of drug development has benefitted from influences and learnings across different disease areas.

Methods: Congress-invited reflection on internal and external efforts to develop new treatments for Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.

Results: Drug development is beginning to leverage the similarities and accommodate the differences across these neurodegenerative diseases. We are targeting Alzheimer’s disease, Parkinson’s disease and Huntington’s disease with treatments that have overlapping mechanisms of action. The clinical development programs for all of these diseases are segmented according to stages, beginning with asymptomatic stages and including prodromal stages to define desirable populations in which to intervene. In addition, research tools, including biomarkers and sensitive digital outcome measures, are being developed on the bases of shared technologies.

Conclusion: Successful leveraging of learnings from one disease to another are expected to speed drug development for all.

Hide